Polyactin A increases CD4+ T-cell counts in HIV-infected individuals with insufficient immunologic response to highly active antiretroviral therapy

We conducted a study to determine whether an immunomodulator, polyactin A, is able to enhance the immunologic response in patients with insufficient immunologic response to highly active antiretroviral therapy. From 783 patients, 48 were eligible and were randomly assigned to an experimental group receiving polyactin A for 3 months or a control group. CD4+ T-cell counts in the experimental group increased from 201 ± 31 to 228 ± 38 cells/µl after treatment (p < 0.001). CD4+ T-cell counts in the control group and CD8+ T-cell counts and CD4+/CD8+ ratios in both groups did not differ significantly between baseline and month 3. The experimental group had a higher CD4+ T-cell count than the control group at month 3 (228 ± 38 versus 205 ± 35, p < 0.05). Our work demonstrated that polyactin A can increase CD4+ T-cell counts in patients with insufficient immunologic response to highly active antiretroviral therapy, but further studies are required to determine its clinical benefits.

[1]  D. Nash,et al.  High Levels of Adherence and Viral Suppression in a Nationally Representative Sample of HIV-Infected Adults on Antiretroviral Therapy for 6, 12 and 18 Months in Rwanda , 2013, PloS one.

[2]  Abdel Babiker,et al.  Long-Term Effects of Intermittent IL-2 in HIV Infection: Extended Follow-Up of the INSIGHT STALWART Study , 2012, PloS one.

[3]  Y. Lévy,et al.  IL-2 immunotherapy in chronically SIV-infected Rhesus Macaques , 2012, Virology Journal.

[4]  B. Gazzard,et al.  Discordant responses on starting highly active antiretroviral therapy: suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study * , 2010, HIV medicine.

[5]  C. Katlama,et al.  High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  H. Lane,et al.  Interleukin-2 therapy in patients with HIV infection. , 2009, The New England journal of medicine.

[7]  Giulia Marchetti,et al.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  A. Westfall,et al.  Clinical Outcome of HIV-Infected Antiretroviral-Naive Patients With Discordant Immunologic and Virologic Responses to Highly Active Antiretroviral Therapy , 2008, Journal of acquired immune deficiency syndromes.

[9]  M. Leal,et al.  Patients' characteristics and clinical implications of suboptimal CD4 T-cell gains after 1 year of successful antiretroviral therapy. , 2008, Current HIV research.

[10]  Mardge H. Cohen,et al.  Factors associated with poor immunologic response to virologic suppression by highly active antiretroviral therapy in HIV-infected women. , 2006, AIDS research and human retroviruses.

[11]  Hai-tao Hu,et al.  [Tumor-suppression effect of polyactin A combined with GM-CSF, TNF-alpha and IL-4 on cord blood mononuclear cells]. , 2005, Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences.

[12]  E. Nicastri,et al.  Clinical outcome after 4 years follow‐up of HIV‐seropositive subjects with incomplete virologic or immunologic response to HAART , 2005, Journal of medical virology.

[13]  A. Telenti,et al.  CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. , 2003, Archives of internal medicine.

[14]  Joseph Quinn,et al.  Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults , 2001, AIDS.

[15]  J. J. Henning,et al.  Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents, January 28, 2000 , 1998, HIV clinical trials.

[16]  Liu Yaqing,et al.  The effect of polyactin A on the lymphocyte immunofunction of the tumor patient , 1995 .

[17]  P. Wang,et al.  Influences of Polyactin A on activities of human monocytes in vitro. , 1991, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[18]  P. Wang,et al.  Influences of a novel immunopotentiator polyactin A on interleukin 1 production and responsiveness in mice. , 1991, Zhongguo yao li xue bao = Acta pharmacologica Sinica.

[19]  R. Kumar.  ImmunovIrologIcal dIscordance In HIv , 2012 .

[20]  Tang Si-quan.  Immune modulatory and therapeutic effect of Mannatide Capsules on perennial allergic rhinitis , 2009 .

[21]  C. Speil.  Incomplete Peripheral CD4+ Cell Count Restoration in HIV-Infected Patients Receiving Long-Term Antiretroviral Treatment , 2009 .

[22]  Huang Yan-mei.  Curative effect of IFN combined mannatide on chronic hepatitis B , 2008 .

[23]  X. Zeng.  Experimental research on immunological activity of Polyactin A. , 1993, Southeast Asian Journal of Tropical Medicine and Public Health.

[24]  Zeng Xy.  Experimental research on immunological activity of Polyactin A. , 1993 .

[25]  H. Wang,et al.  [Effects of polyactin A on in vitro IL-2 production and responsiveness of human lymphocytes]. , 1990, Yao xue xue bao = Acta pharmaceutica Sinica.